Institutional Investors Are Betting On Alkermes Inc (NASDAQ:ALKS)

Sentiment for Alkermes Inc (NASDAQ:ALKS)

Alkermes Inc (NASDAQ:ALKS) institutional sentiment increased to 1.45 in 2019 Q2. Its up 0.35, from 1.1 in 2019Q1. The ratio is more positive, as 97 investment professionals opened new and increased holdings, while 67 decreased and sold equity positions in Alkermes Inc. The investment professionals in our partner’s database reported: 148.59 million shares, down from 148.89 million shares in 2019Q1. Also, the number of investment professionals holding Alkermes Inc in their top 10 holdings was flat from 1 to 1 for the same number . Sold All: 21 Reduced: 46 Increased: 62 New Position: 35.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The company has market cap of $3.80 billion. The companyÂ’s marketed products include ARISTADA for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It currently has negative earnings. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy.

The stock increased 4.66% or $1.03 during the last trading session, reaching $23.13. About 942,697 shares traded. Alkermes plc (NASDAQ:ALKS) has declined 47.26% since September 12, 2018 and is downtrending. It has underperformed by 47.26% the S&P500.

Analysts await Alkermes plc (NASDAQ:ALKS) to report earnings on October, 22. They expect $-0.39 earnings per share, down 387.50 % or $0.31 from last year’s $-0.08 per share. After $-0.06 actual earnings per share reported by Alkermes plc for the previous quarter, Wall Street now forecasts 550.00 % negative EPS growth.

Meditor Group Ltd holds 4.05% of its portfolio in Alkermes plc for 892,400 shares. First Light Asset Management Llc owns 228,023 shares or 0.71% of their US portfolio. Moreover, Bogle Investment Management L P De has 0.54% invested in the company for 303,400 shares. The California-based Primecap Management Co Ca has invested 0.39% in the stock. Spark Investment Management Llc, a New York-based fund reported 215,300 shares.

Alkermes plc (NASDAQ:ALKS) Ratings Coverage

Ratings analysis reveals 0 of Alkermes plc – Ordinary Shares’s analysts are positive. Out of 4 Wall Street analysts rating Alkermes plc – Ordinary Shares, 0 give it “Buy”, 0 “Sell” rating, while 4 recommend “Hold”. The lowest target is $2700 while the high is $3300. The stock’s average target of $29.50 is 27.54% above today’s ($23.13) share price. ALKS was included in 5 notes of analysts from May 1, 2019. Morgan Stanley upgraded Alkermes plc (NASDAQ:ALKS) on Thursday, September 5 to “Equal-Weight” rating. Citigroup downgraded Alkermes plc (NASDAQ:ALKS) on Wednesday, May 1 to “Neutral” rating. Goldman Sachs upgraded the stock to “Neutral” rating in Monday, July 15 report.

More notable recent Alkermes plc (NASDAQ:ALKS) news were published by: which released: “Immunomedics, Inc. (IMMU), Alkermes plc, Inc. (ALKS) and DXC Technology Company (DXC) and YRC Worldwide Inc. (YRCW): Bronstein, Gewirtz & Grossman, LLC Class Action Update – GlobeNewswire” on February 19, 2019, also with their article: “Alkermes President/COO Robinson resigns – Seeking Alpha” published on April 08, 2019, published: “Alkermes Becomes Oversold (ALKS) – Nasdaq” on June 06, 2019. More interesting news about Alkermes plc (NASDAQ:ALKS) were released by: and their article: “Alkermes advancing ALKS 4230 in kidney cancer and melanoma – Seeking Alpha” published on June 12, 2019 as well as‘s news article titled: “Alkermes EPS beats by $0.21, beats on revenue – Seeking Alpha” with publication date: July 25, 2019.

Alkermes plc (NASDAQ:ALKS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.